In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracyclineregulated promoter. In these cells the induction of wildtype p53 leads to signi®cant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sucient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also eectively increase cell death when a transcriptionallydefective p53, p53 [gln22ser23] , is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53
Introduction
Genotoxic and hypoxic stresses trigger the activation of wild-type p53 (reviewed in Giaccia and Prives, 1998; Oren, 1999) . Active p53 helps maintain genomic stability through the induction of either apoptosis or growth arrest at the G1/S and G2/M phases of the cell cycle. Numerous studies have demonstrated that the mutant p53 proteins found in many forms of cancer are defective in causing growth arrest and apoptosis (reviewed by Ko and Prives, 1996; Gottlieb and Oren, 1996; Levine, 1997; WallaceBrodeur & Lowe, 1999; Ryan et al., 2001) . Animal models support the critical role of the apoptotic function of p53 in preventing tumorigenesis (Attardi and Jacks, 1999) .
The most well studied function of p53 is its ability to serve as a sequence-speci®c transcriptional activator of genes that contain p53-responsive elements (Prives and Hall, 1999) . There is an expanding list of p53 target genes whose expression is directly up-regulated in response to induction and activation of p53 presumably through the ability of p53 to bind speci®cally to sites within the vicinity of their promoters. p53 can also repress transcription of a signi®cant number of cellular genes and can do so by distinct mechanisms such as through its ability to interact with the co-repressor m-Sin3A (Murphy et al., 1999 and references therein) .
The p53 protein contains features characteristic of transcriptional regulators including a bi-partite transactivation region at the N-terminus (residues 20 ± 40 and 40 ± 60), a sequence-speci®c DNA binding domain within the central protease-resistant core (residues 100 ± 300) and a tetramerization domain within the C-terminus (residues 325 ± 355). A number of p53 variants have been constructed that provide information as to how the domains and functional regions of p53 are organized. Mutation of two residues in the activation domain, L22Q and W23S, designated p53 [22/23] , abrogates or at least impairs both the transactivation and repression functions of p53 (Lin et al., 1994) . This may be related to the requirement of these two residues for p53 interactions with TAFs (Lu and Levine, 1995; Thut et al., 1995) and p300/ CBP (Avantaggiati et al., 1997; Gu et al., 1997; Lill et al., 1997) . There are two additional regions on p53 that play roles in its functions. One is within the Nterminal region spanning residues 60 ± 90 (proline-rich domain) that contains ®ve copies of the sequence PXXP, and plays a role in p53-mediated apoptosis (Walker and Levine, 1996; Sakamuro et al., 1997; Venot et al., 1998; Zhu et al., 1999) . The second is a basic region within the last 30 amino acids that can regulate the sequence-speci®c interactions of the central region with DNA (reviewed in Jayaraman and and contributes to the ability of p53 to recognize several forms of DNA which resemble structures occurring as a result of DNA-damaging agents Lee et al., 1995; Jayaraman and Prives, 1995; Bayle et al., 1995) .
p53 is heavily modi®ed in vivo at several phosphorylation and acetylation sites, and a number of studies have documented that such sites become modi®ed in response to speci®c stimuli (reviewed by Giaccia and Prives, 1998; Meek, 1999; Appella, 2001) . There is also an extensive body of literature documenting that speci®c modi®cations can aect important aspects of p53 function in vitro such as sequence-speci®c DNA binding and protein ± protein interactions (Jayaraman and Meek, 1999; Appella and Anderson, 2000) . Furthermore protein kinases such as ATM, ATR, Chk1 and Chk2 that can phosphorylate p53 in vitro have been documented to be able to aect the levels of phosphorylation of p53 in vivo (Tibbetts et al., 1999; Banin et al., 1998; Canman et al., 1998; Chehab et al., 2000; Shieh et al., 2000) . While results of studies in which modi®cation sites have been mutated have led to contradictory results, it is reasonable to assume that stress-induced modi®ca-tions of p53 play important roles in stabilization and activation of p53.
It is not fully understood why p53 induces arrest in some cases or cell death in others although these responses appear to be dierentially regulated. Cell cycle arrest is likely to be due to the ability of p53 to activate genes such as p21 (el-Deiry et al., 1993; Harper et al., 1993; Xiong et al., 1993 ), 14-3-3s (Hermeking et al., 1997) or GADD45 (Kastan et al., 1992) . The role of p21 in G1 arrest is quite well understood: it inhibits the activity of G1 cyclin/CDK complexes thereby preventing the phosphorylation and consequent inactivation of the retinoblastoma protein (reviewed in Boulaire et al., 2000) . p21 can also play a role in p53-mediated G2 arrest, but it is likely that in this case it cooperates with other p53 G2-regulatory targets such as 14-3-3s (Chan et al., 2000) or GADD45 (Zhan et al., 1999) .
How p53 causes an apoptotic response is less clear. A number of p53-responsive genes have been identi®ed which are potentially important in the formation of an apoptotic response including the Bax gene (Miyashita and Reed, 1995) , the insulin-like growth factor binding protein 3 (IGF-BP3) gene (Buckbinder et al., 1995) , the PIG genes , Fas/APO1 (Owen-Schaub et al., 1995) , KILLER/DR5 (Wu et al., 1997) , cyclin G (Okamoto and Prives, 1999) , NOXA (Oda et al., 2000a) , AIP1 (Oda et al., 2000b) and others (reviewed in el-Deiry, 1998). There are, however, con¯icting reports as to the role of transactivation in p53-mediated apoptosis. Numerous studies have shown that p53 can induce apoptosis in some cases in a manner that does not require transcriptional activation (Caelles et al., 1994; Wagner et al., 1994; Haupt et al., 1995) , while other studies have demonstrated a requirement for transcriptional regulation by p53 Sabbatini et al., 1995; Attardi et al., 1996; Jimenez et al., 2000; Chao et al., 2000) suggesting that cell type or environment may in¯uence the requirement for functions of p53 involved in apoptosis. The Cterminus of p53 may play a critical role in some cases: showed that microinjection of the C-terminus of p53 into cells induced apoptosis, while Chen et al. (1996) found that cells overexpressing a transcriptionally-competent p53 variant lacking the C-terminal 30 amino acids (p53DC30) were impaired in undergoing apoptosis when compared to cells expressing comparable quantities of wild-type p53. Although wild-type p53 can induce FAS/APO1 expression there is also evidence that altered localization of FAS/APO1 receptor may be the result of a transcription-independent function of p53 (Bennett et al., 1998) .
The intriguing question as to how cells decide to undergo arrest or apoptosis in response to p53 induction has been addressed experimentally. In some cases regulation of the levels of cellular p53 protein from low to high is sucient to determine whether cells arrest or die, respectively (Chen et al., 1996; Ronen et al., 1996) . In the presence of interleukin-3, murine hematopoietic cell lines undergo arrest in response to irradiation, but in the absence of the survival factor apoptosis occurs (Canman et al., 1995; Gottlieb et al., 1994) . Several studies have demonstrated that expression of the anti-apoptotic protein Bcl-2 abrogates p53-mediated apoptosis but not growth arrest (Chiou et al., 1994) . Additionally, in some cases p53-mediated p21-dependent growth arrest has been reported to suppress an apoptotic response (Polyak et al., 1996; Wang and Walsh, 1996; Gorospe et al., 1996; Lu et al., 1998; Bissonnette and Hunting, 1998; Yu et al., 1998; Asada et al., 1999) . Related to this are the existence of p53 mutants that retain the ability to induce growth arrest but not apoptosis (Kobayashi et al., 1995; Rowan et al., 1996) . This may be related to their selective inability to induce pro-apoptotic genes such as bax (Friedlander et al., 1996; Ludwig et al., 1996) .
The p53 status of tumor cells is likely to impact the outcome of cancer therapy and prognosis (reviewed in Peller, 1998; Weller, 1998; Ferreira et al., 1999) . Currently the treatment of cancer relies heavily upon radiation and chemotherapy. Since an important goal of cancer therapy is the induction (or introduction) of wild-type p53 in tumors in conjunction with chemotherapy and radiation treatment it will be critical to identify those agents that can cooperate with p53. Here we have exploited a series of H1299 cell clones engineered to express tetracycline-regulated inducible wild-type or mutated forms of p53. These lines have allowed us to assess in a well-controlled fashion the impact of p53 status on the response of isogenic cells to various chemotherapeutic agents.
Regions of p53 needed for response to chemotherapy N Baptiste et al
Results

p53 protein levels are not affected by treatment with chemotherapeutic agents in H1299 cells
We previously demonstrated that, in clones of Saos-2 and H1299 cells expressing inducible p53, relatively low levels of the protein induce arrest while higher levels cause an apoptotic phenotype (Chen et al., 1996) . Interestingly, p53 in Saos-2 cells can also cooperate with the DNA-damaging agent, camptothecin, to induce apoptosis of cells without a concomitant increase in the level of p53 protein (Chen et al., 1996) . In this study we have extended this observation using H1299 stable clones expressing tetracycline-regulated wild-type or mutant forms of p53. Numerous chemotherapeutic agents commonly used in cancer treatment generate DNA damage. We examined the ability of these drugs to sensitize cells to p53-dependent apoptosis. The agents used include (1), camptothecin (CPT), a topoisomerase I inhibitor (D'Arpa and Liu, 1989) ; (2) (Grem, 2000) . The experimental design was to withdraw tetracycline from one half of the cell cultures at the time of plating. Forty hours later cells were treated with the various compounds in presence or absence of tetracycline. This permitted comparison of the eects of drugs on essentially identical populations of cells with or without expression of p53. The 40 h time point was chosen after plating, since by this time the withdrawal of tetracycline caused a functional G1 and G2 arrest, and p53 is maximally expressed at this time point (Chen et al., 1996 ; and data not shown). The compounds listed above were pre-tested over a wide (50-fold) concentration range in order to determine the optimum quantities to use in each case (data not shown).
H1299 cells that contain inducible wild-type p53 (clone H24 ± 14) were treated as above and cell extracts were subjected to SDS ± PAGE and Western blotting to determine p53 levels ( Figure 1, top panel) . Importantly, levels of wild-type p53 were not aected by any of the agents used. Modi®cation of p53 at a number of sites has been shown to occur in several cell types in response to numerous agents that cause damage to DNA. One particular site, S15, is phosphorylated in vitro by several protein kinases that can regulate p53 in vivo. It was of interest to determine whether phosphorylation at this site occurs under the conditions used in this study. p53 was induced or not in the presence or absence of the ®ve compounds mentioned above, followed by preparation of cell extracts, resolution by SDS ± PAGE and Western blotting using an antibody which is speci®c for p53 phosphorylated at S15 (Figure 1 , second panel). There was greatly increased phosphorylation of S15 on wildtype p53 when cells were treated with each of these compounds, with the exception of colchicine where the increase was very modest. We also examined the induction of two p53 targets, p21, and the apoptosisrelated gene, PIG3, in these cells. Expression of both targets, was correlated with induction of p53 and was not further augmented following drug treatment ( Figure  1 , third and fourth panels). Furthermore, there was no correlation between phosphorylation at serine 15 and induction of either p21 or PIG3.
Numerous chemotherapeutic agents sensitize H1299 cells to apoptosis in a p53-dependent manner
Flow cytometric analysis of H24 ± 14 cells stained with propidium iodide was performed to determine the eects of the various drugs mentioned above upon the cell cycle distribution (Figure 2 ). In the absence of drug treatment, when p53 was maximally induced there was a consistent and signi®cant decline in the per cent of cells in S phase from *25% to 510%. A signi®cant increase in G2/M cells was concomitantly observed. Since the per cent of cells in S phase decreased while G1 cells did not decrease, this indicates that there was a p53-mediated block in G1 as well. With p53 present all agents that were tested caused a further reduction in S phase cells.
A typical example of the impact of wild-type p53 status with and without daunorubicin treatment on cell cycle distribution is shown in Figure 2a . Such Figure 1 Relative expression of wild-type p53, p53-target genes and phosphorylation at serine 15 following treatment with chemotherapeutic agents. The H24 ± 14 clonal derivative of H1299 cells were maintained in medium containing tetracycline. To induce p53, cells were incubated in tetracycline-free medium for 40 h and then either untreated or treated with the indicated compounds for an additional 48 h. Cell extracts were prepared and resolved by SDS ± PAGE followed by transfer to nitrocellulose membranes. Blots were probed with antibodies for p53, antiphosphoS15 antibody, p21, PIG3 or actin as indicated. Protein expression following treatment with no drug, camptothecin (CPT), colchicine (Colc), daunorubicin (Dauno), etoposide (Etop) or 5-¯uorouracil (5-FU) at concentrations described in Materials and methods are shown histograms were obtained for each of the antineoplastic compounds at 24, 48 and 72 h after treatment with these agents, in all cases at least twice, and in some cases several times. The results obtained were highly reproducible and statistically signi®cant. To condense into the most meaningful data given space constraints, we present the numbers from the 48 h time point obtained in representative experiments with each compound ( Figure 2b) . Most of the compounds tested altered the cell cycle distribution of uninduced cells. Without p53, camptothecin and 5-FU caused an increase of cells in S phase in agreement with previous reports (Darzynkiewicz et al., 1996; Thomas and Zalcberg, 1998; Bunz et al., 1999) , while exposure to colchicine and daunorubicin increased the percentage of cells with a DNA content of G2/M cells. Since these assignments are not very precise we cannot assess whether, for example, 5-FU treatment caused accumulation at the G1/S boundary, or whether etoposide caused a very late S phase arrest. In all cases, however, if p53 was fully induced at time of drug treatment, its eects on the cell cycle appeared to predominate. This included a dramatic decrease in S phase cells after each treatment, and with camptothecin, colchicine and etoposide there were signi®cant increases in cells with G1 content of DNA.
Most relevant to this study was the increase in cells undergoing apoptosis, as evidenced by their sub-G1 content, which occurred as a consequence of cooperation between p53 and the various agents. Induction of p53 in the absence of any drug led to only a small increase in the amount of sub-G1 cells. Treatment with all compounds in the absence of p53 also caused a modest sub-G1 increase in such cells compared to untreated cells. Colchicine treatment, in the absence of p53, caused a signi®cant sub-G1 population that was not further increased by the expression of p53. On the other hand, daunorubicin and 5-FU both induced inecient p53-independent apoptosis alone but were able to synergize with p53 in causing the accumulation of apoptotic cells. In all cases where p53-mediated apoptosis after drug treatment was noted, the response was detected as early as 24 h post treatment and by 72 h the majority of the cells were apoptotic (data not shown).
We also determined whether pre-treatment of cells prior to induction of p53 aected the relative sensitization of cells to apoptosis. The results, obtained by reversing the order of expression/treatment, were essentially similar to those described above (data not shown). It should be mentioned that by the 72 h time point, many of the drugs (in addition to colchicine) caused an absolute increase in sub-G1 cells (relative to untreated cells not expressing p53) in the range of 10 ± 19% indicating that they each can cause a p53-independent apoptotic response. This suggests that p53 serves to markedly accelerate the rate of apoptosis in drug-treated cells.
We went on to analyse cells treated as above using another method for measuring apoptosis (Figure 3 ). In the early stages of apoptosis, phosphatidylserine is redistributed to the outer lea¯et of the plasma membrane and this surface exposure can be measured by the binding of Annexin V-FITC (Fadok et al., 1992; Martin et al., 1995) . To con®rm and extend results determining sub-G1 cells by propidium iodide staining, we employed an Annexin V binding assay that, coupled with FACS analysis, provides an independent measure of programmed cell death (Figure 3) . Histograms from an experiment examining the eect of daunorubicin are shown in Figure 3a . Cells exhibited low Annexin V binding both in the absence of daunorubicin whether or not wild-type p53 was expressed (Figure 3a , upper left and right panels) and when cells were treated with this drug in the absence of wild-type p53 (Figure 3a , lower left panel). However, daunorubicin treatment in the presence of wild-type p53 resulted in dramatically increased Annexin V binding. The graph in Figure 3b summarizes the results obtained with all of the chemotherapeutic agents that were tested. Signi®cant p53-dependent increases in Annexin V binding were seen with daunorubicin, camptothecin and 5-FU, while etoposide showed a more moderate p53-dependent increase. Colchicine showed a p53-independent increase in Annexin V binding compared with controls. The above results were highly consistent with the data estimating sub-G1 DNA cells using propidium iodide staining, thus supporting the conclusion that in H1299 cells several chemotherapeutic agents sensitize cells to p53-mediated apoptosis.
Regions of p53 involved in cooperation with chemotherapeutic agents
To determine whether regions (or functions) of p53 can be identi®ed that are responsible for its ability to induce apoptosis in cells treated with various drugs, a similar approach was taken using H1299 clones expressing a series of mutant forms of p53. The p53 variants studied included wild-type p53, p53 [22/23] , which is impaired in transactivation/repression; p53DC30, in which the C-terminal 30 amino acids have been deleted; and p53Dpro, which lacks the PXXP containing region between residues 62 and 91. Shown in Figure 4a (left panel), are p53, p53 [22/23] , p53DC30 and p53Dpro protein levels determined at 48 h after removal of tetracycline. Although the levels of these four p53 variants diered we believe that these dierences do not aect interpretation of the data. In the case of p53 [22/23] , many of our earlier experiments were performed with another clone of cells expressing p53 [22/23] at lower levels (see Figure 4a , right panel) and essentially identical results were obtained with clones expressing high or low levels of this p53 variant. Clones of H1299 cells expressing tetracycline-regulated wildtype p53, p53 [22/23] , p53DC30, and p53Dpro cells were treated with the agents as above, histogram results were obtained of propidium iodide treated cells and cell cycle analyses were generated. Figure 4b summarizes the extent of apoptosis, as measured by proportion of sub-G1 cells, in the dierent cell lines before and after treatment with the compounds described above, with and without expression of p53. We discuss the results obtained with each p53 variant as follows:
A subset of drugs do not require full transcriptional activity of p53 to induce apoptosis The double mutant p53 [22/23] is well documented to be signi®cantly impaired in transactivation and repression of wild-type p53 targets. As discussed in the Introduction, contradictory results have been obtained as to whether p53 [22/23] can cause cell death, and so it was of considerable interest to determine whether the cooperative eects of wild-type p53 with the various chemotherapeutic compounds could be extended to this transcriptionally-impaired version of p53. Initially, the cell line H22/23-6 was used which, as shown in Figure  4a [22/23] -expressing cell line, H22/ 23-5 that expresses signi®cantly greater quantities of p53 than in the wild-type p53 expressing line H24 ± 14 (Figure 4a, left panel) . In either case induction of this mutant protein did not cause detectable growth arrest (data not shown) and in both cases essentially identical results were obtained. Expression of p53 [22/23] in untreated samples caused no increase whatever in the per cent of sub-G1 cells, which was in contrast to wildtype p53 that caused a small increase in the number of apoptotic cells in the absence of drug treatment. By contrast, substantial increases in the percentage of cells with sub-G1 content from either the H22/23-6 (not shown) or H22/23-5 (Figure 4b ) cell line were observed after treatment with several of the compounds. Although, as seen with wild-type p53, there was no signi®cant increase in sub-G1 DNA after treatment of cells with colchicine, apoptosis was markedly increased in camptothecin, daunorubicin and etoposide treated cells that expressed p53 [22/23] . Moreover, the cooperation with etoposide, as measured by both fold increase and absolute values, was greater than that seen with the wild-type protein. The eects of camptothecin were similar with wild-type p53 and p53 [22/23] while with daunorubicin they were somewhat less marked. Thus, p53 [22/23] cooperates with all of the above compounds approximately similarly to what was seen with wildtype p53. Unexpectedly, however, there was no signi®cantly increased apoptosis upon the addition of 5-FU to cells expressing this mutant form of p53. This result was reproducible over a broad range of concentrations and was obtained with both high (H22/23-5) and low (H22/23-6) producing p53 [22/23] clones. At all time points the absolute increase in the per cent of sub-G1 cells was less than 3% and the fold induction was less than 2. Thus, as opposed to camptothecin, daunorubicin and etoposide, our results indicate that 5-FU aects the ability of p53 to induce apoptosis via a mechanism that depends upon its having a fully functional activation domain. The C-terminus of p53 is not required for induction of apoptosis after treatment with DNA-damaging drugs The region of p53 spanning its C-terminal 30 amino acids was reported to act variously as an autoinhibitory portion of p53 or a DNA damage recognition domain. As was the case with wild-type p53, the Cterminally truncated p53DC30 induced a small amount of apoptosis in the absence of any drug treatment. Additionally, we observed sensitization of p53DC30 expressing cells to apoptosis following treatment with camptothecin, daunorubicin and etoposide but not with colchicine. Cooperation with 5-FU was observed as Figure 4 The PXXP domain of p53 is required for its ability to induce apoptosis in response to treatment with dierent chemotherapeutic agents. (a) Extracts of H1299 cells engineered to express wild-type p53, p53 [22/23] (22/23), p53DC30 (D30), and p53Dpro (D62-91) were induced by withdrawal of tetracycline, and analysed by Western blotting using PAb 1801 as in Figure 1 . All are clonally-derived cell lines generated from the parental cell line H24. In the left panel the p53 [22/23] protein is derived from the H24p53 (22/23)-5 cell line, while in the right panel the p53 [22/23] protein is derived from the H24p53 (22/23)-6 cell line. (b) Cell lines expressing p53 variants with the compounds indicated were treated as described in Materials and methods and Figure 2 . FACS analysis was used to obtain values for per cent sub-G1 cells following treatment with the various drugs. The bars (open, without p53; striped, with p53) show the per cent of cells with sub-G1 DNA content at 48 h after treatment with the various agents. Abbreviations are as in Figure 1 . The results shown are the averages of at least three experiments well, albeit not to the same extent as wild-type p53. This may be due to the fact that this clone expresses signi®cantly less p53 protein than does the clone expressing wild-type p53. Thus, the ®nal 30 amino acids of p53 do not appear to be critical for its ability to respond to DNA-damaging agents to cause cell death.
The proline-rich domain is necessary for p53 cooperation with anti-neoplastic agents The region on p53 between residues 60 and 90 containing ®ve copies of the sequence PXXP plays a role in p53-mediated suppression of cell growth and apoptosis. Since the other p53 variants were either inert or greatly attenuated in inducing apoptosis unless cells were treated with the anti-neoplastic agents, it was of particular interest to determine whether p53Dpro could also be`activated' under similar conditions. In fact, as shown in Figure 4b , cells expressing p53Dpro were incapable of cooperating with any of the agents tested to induce apoptosis as measured by increase in sub-G1 DNA cells. p53Dpro protein levels were similar to those of wild-type p53 in H24 ± 14 cells ( Figure 4a ) and these levels were not aected by treatment with any agents used (Figure 5b) . Thus, the PXXP region is required for the ability of p53 to cooperate with anti-neoplastic agents to promote cell death.
To gain further information about the results obtained with p53 [22/23] and p53Dpro we went on to examine the phosphorylation of both at S15 and the induction of p53 targets by p53Dpro ( Figure 5 ). As had been observed with wild-type p53 both versions of p53 displayed increased phosphorylation at S15 after treatment with all agents other than colchicine which showed no increase over p53 in untreated cells. p53 [22/23] in these cells was`basally' phosphorylated at this residue, although it was further phosphorylated after treatment with these agents. As had been demonstrated with wild-type p53, treatment of cells expressing these two p53 variants with various drugs had no eect on the levels of p53 protein (see Figure 5a ,b). The ability of p53Dpro to induce p21 was not signi®cantly aected by treatment with any drug, although in this case daunorubicin treatment did cause a signi®cant increase in the levels of p21 protein. Strikingly, however, in contrast to what was seen with wild-type p53, cells expressing p53Dpro were markedly less eective at inducing PIG3 and, in fact, treatment with the various agents either reduced (CPT and 5-FU) or nearly eliminated (colchicine, daunorubicin and etoposide) PIG3 expression ( Figure  5b ). Although PIG3 levels were not augmented under any condition in cells expressing p53 [22/23] it is noteworthy that a small amount of p21 was induced in response to this form of p53 suggesting that it is transcriptionally impaired but not completely defective (data not shown).
p21 alone does not induce apoptosis in cells treated with chemotherapeutic agents
Although, as described in the Introduction, p21 expression has been shown in several cases to decrease apoptosis, it was possible that in our conditions, it might still be responsible for the ability of p53 to cooperate with one or more of the compounds to facilitate cell death under the conditions of our experiments. In fact, while p53Dpro was competent to induce p21 expression, it was signi®cantly less ecient than wild-type p53 at doing so. Furthermore, treatment with various agents did not appear to increase the ability of this mutant to induce p21 expression. This led us to test whether p21 might itself be involved in mediating the ability of p53 to cooperate with agents to cause cell death. To test this H1299 cells containing tetracycline-regulated p21 were used. Upon p21 induction, with or without treatment with the same compounds as above, cells were subjected to FACS analysis to assess the extent of apoptosis as measured by quantities of sub-G1 cells. Levels of p21 were similar to or greater than those seen when wild-type p53 is induced in these cells (not shown), but were not further increased after treatment with any agents, and no signi®cant apoptosis was induced in any condition (Figure 6 ). Thus the ability of anti-neoplastic agents to sensitize H1299 cells to p53-mediated apoptosis is independent of p21 expression.
Discussion
An important goal of p53 gene therapy would be to establish therapeutic conditions that favor the ability of Figure 5 Expression and modi®cation of p53 [22/23] and p53Dpro. (a) p53 [22/23] protein levels (PAb 1801) and phosphorylation at S15 were determined as in Figure 1 following treatment with the indicated agents. (b) Relative expression of p53Dpro, p21, PIG3, actin or p53Dpro phosphorylated at serine 15 following treatment with the indicated agents was determined as in Figure 1 the protein to cause cell death. In this study we utilized a series of cell lines expressing inducible versions of p53 to (1) identify standard chemotherapeutic agents that can cooperate with p53 to induce apoptosis and (2) evaluate the contributions of dierent regions of p53 required for this cooperation. Our results pose several questions which will hopefully be addressed in future studies:
How do chemotherapeutic agents cooperate with p53 to cause cell death?
Several chemotherapeutic agents were demonstrated to sensitize cells to a p53-dependent apoptotic response. Although these compounds do not fall into one class with a de®ned mechanism of action, one common signal caused by all of these agents is the formation of DNA strand breaks. It would thus be of interest to microinject nucleases, previously shown to activate p53 (Lu and Lane, 1993; Nelson and Kastan, 1994; Nakagawa et al., 1999) , to determine if strand breaks are sucient for the cooperative apoptotic phenotype. Whatever the initiating signal, there is still much to learn about the pathways to p53-mediated apoptosis by DNA damage. Although p53 is phosphorylated at several sites in response to these and other DNAdamaging agents, it is still not fully understood how p53 modi®cation aects its functions. Perhaps more interesting is the recent observation that phosphorylation at S46 of p53 is correlated with p53-dependent apoptosis (Oda et al., 2000b) .
Many of the drugs tested caused some apoptosis in cells not expressing p53, demonstrating that they can trigger a p53-independent pathway for apoptosis. But the per cent of cells undergoing apoptosis and the rate of the apoptotic response was signi®cantly less than when p53 was induced, and in some cases the cooperation between p53 and an agent was synergistic. A p53-independent mechanism of sensing DNA damage, which regulates entry into S phase in CHO cells, has been identi®ed (Lee et al., 1997) . It could be speculated that under some conditions products of the p53-related genes p63 and p73 are responsible for this in H1299 cells, although we as yet have no evidence to support or refute this. One drug in our study, colchicine, caused a large p53-independent apoptotic response and this response was actually slightly inhibited by induction of p53 protein consistent with a previous study in which a similar observation was made with another microtubule inhibitor, taxol (Wahl et al., 1996) . Thus, a possible aim of cancer therapy might be a combination of treatment with compounds that destabilize microtubules along with introduction of p53 into tumor cells in conjunction with agents that trigger p53-dependent apoptosis.
Why does 5-FU fail to cooperate with p53 [22/23] ?
Of the compounds tested 5-FU was unique in facilitating apoptosis induced by wild-type p53 and p53DC30 but not p53 [22/23] . The transcriptionally-impaired p53 [22/23] was found to be defective in both activation and repression of many genes known to be regulated by wild-type p53 (Roemer and Mueller-Lantzsch, 1996 and our unpublished data) and it is not known which aspect(s) of the transcriptionally-impaired mutant form of p53 is responsible for its lack of cooperation with 5-FU. This nucleotide analogue functions both as a speci®c inhibitor of thymidylate synthetase and also works to interfere with RNA and DNA metabolism. It is interesting that Bunz et al. (1999) found that the ability of 5-FU to kill cultured colon cancer HCT116 cells in a p53-dependent manner involves speci®cally the impairment of RNA metabolism by this analogue, rather than its eect on DNA metabolism or thymidylate synthetase. If this is the case in H1299 cells, then the signal to p53 resulting from defective RNA metabolism is unique in that it is restricted to p53 that is fully transcriptionally competent. Our data exclude p21 as an agent of drugmediated apoptosis, and Zhang et al. (2000) recently showed that 5-FU can induce apoptosis in bax-null cells, thus eliminating another known p53 target as a mediator of the 5-FU eect. There may be transcriptional targets of p53 other than p21 or bax that can induce cell death only when RNA metabolism is disturbed. Other forms of stress such as DNA damage would not require activation (or repression) of such a target or targets. We conclude that standard chemotherapeutic agents can cooperate with p53 to induce apoptosis through at least two pathways: one dependent on wild-type transactivation/ repression and one not. It is possible that a broader study of tumors into which p53 is reintroduced would reveal selective defects in one pathway and consequently the cells would be more resistant to a subset of chemotherapeutic agents. How do different regions of p53 contribute to its response to chemotherapeutic agents?
DNA-damaging agents sensitized cells to ecient cell death induced by wild-type p53, p53DC30 and p53 [22/23] (with the exception of 5-FU). By contrast the p53 deleted of the proline-rich region was completely inert in causing apoptosis under any condition tested. We discuss below the implications of results obtained with the dierent p53 variants used.
p53 [22/23] It is tempting to conclude that the p53 [22/23] mutant proves that transcriptional regulation is not necessary for the apoptotic response to p53 under our experimental conditions since it did not induce PIG3 expression nor cause any alteration in cell growth kinetics or cell cycle pro®le (Chen et al., 1996; Zhu et al., 1998 and not shown) . In fact, as mentioned in the Introduction, prior studies have shown that under some circumstances p53 can induce apoptosis through a transcription-independent mechanism. It is important to acknowledge, however, that p53 [22/23] may not be completely transcriptionally inert. This variant was reported to be capable of eliciting approximately 10% of the wild-type ability to activate a reporter in a transient transfection assay (Lin et al., 1994) and its expression in H1299 cells induces the expression of a small number of genes in H1299 cells (Zhu et al., 1998) . Furthermore we have on occasion observed that upon expression of high levels of this variant a small increase in p21 protein is detected (data not shown). Thus, it cannot be excluded that there are one or more targets, which both p53 [22/23] and wild-type p53 either activate or repress, that are the key mediators of apoptosis when cells are treated with DNA-damaging agents. It follows that such targets would not be induced by p53Dpro. Whatever the explanation, our results with p53 [22/23] mutant support the likelihood that the apoptotic response to p53 is complex and must involve at least two if not more pathways. It would be informative to use techniques such as DNA arrays to perform a widespread analysis of the transcriptional response to the p53 variants used in this study to gain insight into these issues.
p53DC30 It was of interest that the C-terminally deleted p53 is similar to wild-type p53 in cooperation with the dierent agents described and others (data not shown). The C-terminus of p53 can bind nonspeci®-cally to dierent forms of DNA such as irradiated DNA (Tang et al., 1999) , mismatched DNA (Parks et al., 1997; Mee et al., 1999; Degtyareva et al., 2000) , DNA with Holliday junctions (Lee et al., 1997) , ends of DNA (Bakalkin et al., 1995; Zotchev et al., 2000) and gapped DNA (Zotchev et al., 2000; J Ahn and C Prives, unpublished) . These observations suggest the possibility that strand breaks and other lesions caused by chemotherapeutic agents might lead to the activation of p53 in a manner that would involve the Cterminus of the protein. The C-terminus might be involved in bringing p53 to sites of damage where it could be activated or modi®ed directly. It was therefore surprising (and disappointing) that p53DC30 did not dier from wild-type p53. This suggests that any modi®cations or other response of p53 would work by mechanisms exclusive of aecting C-terminal regulatory functions.
p53Dpro Our results show that the proline-rich domain of p53 (residues 60 ± 90) is required for its ability to cooperate with anti-neoplastic agents to induce cell death. It is not yet understood how this region functions in the apoptotic response to p53. Sakamuro et al. (1997) have reported that p53 deleted of this region is defective in inducing cell death under conditions where wild-type p53 is highly apoptotic. In fact it can be speculated that the reduced induction of PIG3 expression by p53Dpro after treatment with drugs re¯ects the ability of this region to preferentially induce apoptosis relevant genes under certain conditions. Zhu et al. (1999 Zhu et al. ( , 2000 have generated a large number of p53 variants that also point to this region and also the second activation sub-domain, located between 43 ± 63, as being critical for apoptosis. Walker and Levine (1996) and Sakamuro et al. (1997) reported that the p53 deleted of the proline-rich domain is transcriptionally active, although Venot et al. (1998) found that the transcriptional activity of p53Dpro is selectively compromised in that it can induce p21 but not PIG3, a target associated with p53-dependent apoptosis. Phosphorylation of S46 is correlated with and possibly responsible for p53 induction of AIP1, a mitochondrial pro-apoptotic factor (Oda et al., 2000b) . Taken together these reports suggest that there are at least two subdomains in the N-terminus, that are together required for apoptosis, one between amino acids 40 and 60 and the other being the proline-rich domain spanning residues 60 ± 90 (although one or a few PXXP motifs may suce from this region). These two regions may work together to alter the transcriptional program of p53 towards an apoptotic response. This then poses the question as to whether the results with p53 [22/23] are the result of an alternate (but limited) pro-apoptotic repertoire of transcriptional targets, which p53Dpro lacks, and which is dependent upon the additional signals caused by DNA-damaging agents, or whether by introducing mutations in one region of the Nterminus the function of other regions is altered.
Does cell cycle stage or arrest affect p53-mediated apoptosis?
Numerous studies have demonstrated that prior growth arrest by p53 is not required for a subsequent apoptotic response. Our data strongly support such conclusions. First, apoptosis ensued regardless whether compounds (including 5-FU) were added before or after the induction of growth arrest by wild-type p53 (data not shown). Second, p53 [22/23] does not cause arrest but yet retains the ability to cooperate with a subset of the drugs tested. Third, induction of p21 in the H1299-p21 inducible cell line also causes cell cycle arrest (data not shown) but did not cause apoptosis Regions of p53 needed for response to chemotherapy N Baptiste et al under any conditions tested. In fact, work from several groups has supported the notion that not only does p21 fail to cause apoptosis, it can protect cells from this outcome. Our data show that p21 induction does not aect apoptosis and whatever the mechanism by which p21-mediated arrest can prevent cell death, this is bypassed under the conditions used in our experiments. It should be noted here, nevertheless, that the fact that 5-FU selectively cooperates with transcriptionally-competent forms of p53 (wild-type and p53DC30) may re¯ect a requirement for cells to be arrested in G1 or G2 for this compound to work. The inability of p53 [22/23] to cause cell cycle arrest may thus be responsible for its inability to become pro-apoptotic when cells are treated with this nucleotide analogue.
It is now well documented that expression of oncogenes can sensitize cells to p53-mediated apoptosis (Lowe et al., 1993; Sabbatini et al., 1995; Zindy et al., 1998; Attardi et al., 1996; reviewed in Lowe and Lin, 2000) . The cell lines used in our study derive from a human lung carcinoma and as such must express activated oncogenes, which alone do not provide the cellular environment that allows induction of p53 to cause cell death. Since cooperation between the agents used in this study and p53 occurs even in cells arrested in G1 and G2, it appears that the ability of con¯icting growth signals to induce apoptosis does not require that the cells be cycling. We cannot exclude the possibility that the agents cause some cells to lose their arrest phenotype and as a result undergo apoptosis. However, the apoptosis would have to be immediate as in samples previously arrested by p53 none of the drugs caused an increase in the per cent of cells in S phase.
We have worked with one transformed cell type and it will be of obvious importance to extend them to a much larger panel of tumors to determine the importance of genotype on the eects seen in this study. The results of several studies suggest that a promising strategy to treat tumors is to combine chemotherapy with the reintroduction of p53 (Roth et al., 1996; Sandig et al., 1997; Seth et al., 1997; and reviewed in Gjerset and Mercola, 2000) . Our data supports and extends the work presented in those studies showing that p53 cooperates with several chemotherapeutic agents using more than one mechanism. Indeed, given results showing that p21 expression may ultimately weaken tumors' response to chemotherapy (Waldman et al., 1997) , our results with p53 [22/23] may provide an attractive alternative for p53-based therapies. It is possible that an examination of a panel of dierent tumors will reveal a subset of tumors defective in one or another mechanism following the introduction of p53. Thus the most eective chemotherapeutic agents used to cooperate with reintroduced p53 might vary from patient to patient or even within the dierent cells of a given tumor. It will also be of interest to examine the eects of combinations of the agents. The work presented here provides a basis for more detailed examination in other cell lines and in in vivo settings, with the ultimate goal of providing more eective cancer therapy.
Materials and methods
Cell lines
The cell lines used in this study are all clonally derived from H1299 cells and were generated using the two-step tetracycline-regulated system (Resnitzky et al., 1994) . All but p53Dpro cells were described in Chen et al., 1996 . p53Dpro cells which express wild-type p53 lacking residues 62 ± 91 were constructed as described in Zhu et al. (1998) . The cells were grown in RPMI medium (Gibco) supplemented with 10% fetal bovine serum.
Cell cycle analysis
For cell cycle analysis, 2610 5 cells were seeded per 60-mm plate with or without 4 mg/ml tetracycline. Twenty-four hours later medium was removed from cultures without tetracycline, and replaced with fresh tetracycline-free medium. Forty hours after plating the cells were treated with the various chemotherapeutic agents, and 48 h later the cells were trypsinized and the cells and media pooled and centrifuged at 1500 r.p.m. The pellet was resuspended in 300 ml PBS and then ®xed with 5 ml of ice-cold methanol for at least 1 h at ± 208C. The ®xed cells were then centrifuged and resuspended in 2 ml of cold PBS. After incubation at 48C for at least 30 min, the cells were centrifuged and resuspended in 0.9 ml of PBS solution containing RNase (50 mg/ml) and propidium iodide (PI) (60 mg/ml, Sigma). After incubation at 208C for 30 min, the stained cells were analysed in a¯uorescence-activated cell sorter (FACSCalibur, Becton Dickinson). The percentages of cells in various phases of the cell cycle were analysed using the ModFit LT program. Concentrations of anti-neoplastic agents were: camptothecin (0.18 mM), colchicine (18 mM), daunorubicin (0.22 mM), etoposide (15 mM), and 5-FU (0.5 mM).
Immunoblot analysis
Cells were collected from 60 mm plates by mechanical scraping in cold PBS followed by centrifugation at 10 000 r.p.m. The pellets were resuspended in 16 protein sample buer and boiled for 10 min. Extracts were analysed using a 7.5 or a 12.5% SDS ± PAGE gel and then transferred for 3 h to nitrocellulose. The monoclonal antibody PAb 1801 was used to detect p53 and anti-actin antibodies were purchased from Sigma. The p21 monoclonal antibody, WAF1 (Ab-1), was obtained from CALBIOCHEM. The p53 phosphoserine15-speci®c polyclonal antibody was a kind gift from Y Taya. Enhanced chemiluminescence (Amersham) was used for the detection of proteins. The PIG3 antibody was a generous gift from D Hill (Oncogene Research Products, Cambridge, MA, USA).
Annexin V-FITC staining
Cells were trypsinized and cells and media pooled and centrifuged at 1500 r.p.m. Pellets were washed once with cold PBS and then resuspended in 200 ml of binding buer containing Annexin V-FITC (0.5 mg/ml) and propidium iodide (1.25 mg/ml) (CLONTECH Laboratories, Inc.). After incubation at 208C for 10 min, cells were subjected to FACS analysis.
